OliPass Corporation

A fortnight or so after Vertex Pharmaceuticals Incorporated ’s VX-548 achieved one of the vanishingly few breakthroughs by a non-opioid painkiller, a start-up has emerged to develop a similarly actin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas, Pantherna Expand mRNA Re

South Korea is set for a robust year of initial public offerings (IPOs) by biotech and pharma companies following a substantial rally in the sector last year and the government’s recent move to ease l

South Korea's OliPass Corp. may not be a mainstream antisense drug company, but it has strong ambitions and the confidence to become a top global oligonucleotide therapeutics company with its plat